Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Year: 2015
Type: article
Source: European Journal of Cancer
Authors: Dirk Schadendorf, Mayur M. Amonkar, Daniil Stroyakovskiy, Evgeny Levchenko, Helen Gogas, Filippo de Braud, Jean-Jacques Grob, Igor Bondarenko, Claus Garbe, Celeste Lebbe, James Larkin, Vanna Chiarion-Sileni, Michael Millward, Ana Arance, Mario Mandalà, Keith T. Flaherty, Paul Nathan, Antoni Ribas, Caroline Robert, Michelle Casey, Douglas J. DeMarini, Jhangir G. Irani, Gursel Aktan, Georgina V. Long
Institutions: Essen University Hospital, GlaxoSmithKline (United States), Moscow City Oncology Hospital №62, Institute of Oncology NN Petrov, National and Kapodistrian University of Athens, Fondazione IRCCS Istituto Nazionale dei Tumori, Assistance Publique Hôpitaux de Marseille, Hôpital Sainte-Marguerite, Dnipro State Medical University, Universitätsklinikum Tübingen, University of Tübingen, Inserm, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Diderot, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Royal Marsden Hospital, Istituto Oncologico Veneto, Sir Charles Gairdner Hospital, Hospital Clínic de Barcelona, Ospedale Papa Giovanni XXIII, Massachusetts General Hospital, Mount Vernon Cancer Centre, University of California, Los Angeles, Institut Gustave Roussy, The University of Sydney, Melanoma Institute Australia
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: GlaxoSmithKline
Award: G6950121198
OpenAlex ID: W2111131433